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Abstract: Liver-related death in human immunodeficiency virus
(HIV)-infected individuals is about 10 times higher compared with
the general population, and the prevalence of significant liver fibrosis in
those with HIV approaches 15%. The present study aimed to assess risk
factors for development of hepatic fibrosis in HIV patients receiving a
modern combination anti-retroviral therapy (cART).
This cross-sectional prospective study included 432 HIV patients, of
which 68 (16%) patients were anti-hepatitis C virus (HCV) positive and
23 (5%) were HBsAg positive.
Health trajectory including clinical characteristics and liver fibrosis
stage assessed by transient elastography were collected at inclusion.
Liver stiffness values >7.1 kPa were considered as significant fibrosis,
while values >12.5 kPa were defined as severe fibrosis. Logistic
regression and Cox regression uni- and multivariate analyses were
performed to identify independent factors associated with liver fibrosis.
Significant liver fibrosis was detected in 10% of HIVmono-infected,
in 37% of HCV co-infected patients, and in 18% of hepatitis B virus co-
infected patients. The presence of diabetes mellitus (odds ratio
[OR]¼ 4.6) and FIB4 score (OR¼ 2.4) were independently associated
with presence of significant fibrosis in the whole cohort. Similarly,
diabetes mellitus (OR¼ 5.4), adiposity (OR¼ 4.6), and the FIB4 score
(OR¼ 3.3) were independently associated with significant fibrosis in
HIV mono-infected patients. Importantly, cumulative cART durationne Schwarze-Zander h Boesecke, MD,
D, PhD, and Ju¨rgen Kurt Rockstroh , MD
metabolic disorders, HIV may also have a direct effect on fibrogenesis.
Successful cART leading to complete suppression of HIV replication
might protect from development of liver fibrosis.
(Medicine 94(50):e2127)
Abbreviations: ART = antiretroviral therapy, AZT =
azidothymidine, BMI = body mass index, cART = combination
anti-retroviral therapy, CI = confidence interval, d4T = stavudine,
DDI = didanosine, DM = diabetes mellitus, HBV = hepatitis B
virus, HCV = hepatitis C virus, HIV = human immunodeficiency
virus, HOMA-IR = homeostasis model assessment—insulin
resistance, HR = hazard ratio, HSC = hepatic stellate cells,
IQR = interquartile range, LPVr = lopinavir, LS = liver stiffness,
MSM = men who have sex with men, NAFLD = nonalcoholic fatty
liver disease, NASH = nonalcoholic steatohepatitis, OR = odds
ratio, SVR = sustained virologic response, TE = transient
elastography.
BACKGROUND
I n the era of modern combination anti-retroviral therapy(cART), life expectancy of human immunodeficiency virus
(HIV)-infected patients approaches that of the general popu-
lation if cART is initiated at high CD4 cell counts.1 Therefore,
non-AIDS defining events are increasingly responsible for
morbidity and mortality among aging HIV-infected individ-
uals.2 In particular, liver-related deaths occur 10 times higher
than in the general population,3 ranging between 7% and 14% in
different cohorts4,5 and rendering liver diseases an important
non-AIDS condition in HIV patients. Chronic viral hepatitis B
(HBV) or C (HCV), as well as alcohol abuse or nonalcoholic
steatohepatitis (NASH) induce liver injury with consecutive
fibrosis and might progress to liver cirrhosis with an increased
risk for the development of hepatocellular carcinoma.6 How-
ever, one-third of liver-related deaths is not associated with viral
hepatitis,7 indicating that other than the classic risk factors play
an important role. Several experimental studies indicate that
HIV may also have a direct effect on hepatic fibrogenesis. HIV
enters via CCR5 and CXCR4 and activates the hepatic stellate
cells (HSC), the principle fibrogenic cell type in the liver.8–11
Thus, uncontrolled replication of HIV might enhance hepatic
fibrogenesis directly.
To date, sparse data are available on the prevalence and
potential risk factors for hepatic injury among HIV mono-
infected patients. Interestingly, uncontrolled HIV viral replica-
tion, low CD4þ T cell count, as well as long-term exposure to
antiretroviral regimes were identified as risk factors for the
development of significant liver fibrosis.12 The later seems
somehow contradictory, since cART on one side might protectuppressing HIV viral replication, and on
mote fibrosis due to hepatotoxic effects.
med to assess the risk factors associated
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with the development of clinical relevant liver fibrosis in a large
HIV-cohort from the Infectious Diseases outpatient clinic at
Bonn University, screened by transient elastography (TE)
(FibroScan1 ECHOSENS, Creteil, France).
METHODS
Patients
This cross-sectional prospective study included 432 HIV-
infected patients followed at the Infectious Diseases outpatient
clinic at Bonn University between August 2013 and August 2014.
All patients with confirmed HIV infection were eligible for
inclusion. Blood collection and liver stiffness (LS) measurement
wereperformedona regular scheduledvisit in ouroutpatient clinic.
Informed consent was obtained from each patient included in the
study and the study protocol conforms to the ethical guidelines of
the 1975Declaration of Helsinki as reflected in the approval by the
institution’s human research committee (279/14).
Data Acquisition and Follow-Up
Laboratory work-up of metabolic (HbA1c, cholesterol,
LDH, HDL, triglycerides, transaminases, bilirubin, creatinine,
platelets, albumin, and TSH), inflammatory/immunologic
(CRP, CD4, and CD8), and HIV-relevant disease markers (viral
load) was performed at the time of TE. Demographic and
clinical characteristics, as well as health trajectory of HIV-
infection and antiretroviral treatments were collected from the
patient’s health record and our department’s database. Current
co-medication, alcohol consumption, and smoking status were
recorded and the actual body mass index (BMI) was assessed.
Liver Stiffness Measurement
LSmeasurement was assessed by TE using FibroScan 502
touch1 (ECHOSENS, Creteil, France). TE was performed by
experienced and trained operators using BMI-corresponding
probes. According to manufacturer’s recommendations, only
examinations with at least 10 valid measurements, a low varia-
bility defined as an interquartile range (IQR/M) smaller than 30%
of the median value from an individual scan, and a successful
acquisition rate of >60% were considered reliable and were
approved for analysis. LS values>7.1 kPa (equivalent to Metavir
F  2) were considered abnormal. LS ranging from 7.1 to 12.4
kPa was considered significant fibrosis and values 12.5 kPa
(equivalent to Metavir F  3–4) as severe fibrosis.13,14
Statistical Analysis
Demographic, clinical, and laboratory characteristics stra-
tified by the severity of liver fibrosis were compared. Differences
in continuous variables, expressed as medians and first and third
quartiles were assessed using nonparametric Mann–Whitney
test. Categorical variables, expressed as absolute frequencies
and percentages, were compared using Pearson’s Chi-squared
test or Fisher’s exact tests. A correlation analysis estimated
possible impacts on liver fibrosis determined by TE and serum
scores. Uni- and multivariate analyses were performed using
logistic and Cox regression models. SPSS version 22 (IBM
Corporation, Armonk, NY) was used for statistical analysis.
RESULTS
Mohr et alGeneral Characteristics of the Cohort
Among 432 adults, 78% were male and 79% Caucasian
with a median age of 46 (IQR, 38–53) years. Half of the patients
2 | www.md-journal.comwere men who have sex with men. The baseline characteristics
of the subjects included are shown in Table 1.
Twenty-three (5%) patients were HBsAg positive, 68
(16%) were anti-HCV positive, of which 37 (54%) had achieved
sustained virologic response (SVR) and 31 (46%) were HCV-
RNA positive. Three (0.7%) were HBsAg positive and anti-
HCV positive, and 343 (80%) were HIV mono-infected. The
vast majority (95%) received cART, and the median duration of
HIV infection was 10 (IQR, 5–15) years. One hundred fifteen
(27%) patients were classified as CDC category C. The median
CD4þ T cell count was 550 cells/mm3 (IQR 367–698). Seventy
patients of the total population (17%) had detectable HIV
viremia (defined as >40 copies/mL), of which 19 (27%) were
ART naive and 51 (73%) were under cART. Of all patients
receiving cART 87% had undetectable HIV viremia and 5% had
a viral load <200 copies/mL. With regard to the 68 HIV/HCV
co-infected patients, 37 (54%) achieved an SVR, 21 (31%) were
HCV therapy naı¨ve, and 10 (15%) either relapsed or were
nonresponder to previously administrated HCV treatments.
LSM at Inclusion
Among all patients with valid LS measurements (n¼ 413),
9% (37/413) had significant fibrosis (FibroScan value 7.1–12.4
kPa) and 3% (13/413) had severe fibrosis (FibroScan value
12.5 kPa). As expected, a markedly higher prevalence of
fibrosis was found in the patients with chronic hepatitis C
(patients with positive HCV-RNA, n¼ 31) or hepatitis B co-
infection (patients with positive HBsAg, n¼ 23), namely 37%
and 18%, respectively. However, patients with HCV antibodies
and a history of SVR after successful HCV therapy (n¼ 37) did
not show a significantly higher rate of abnormal LS (13%).
Most interestingly, 8% (26/327) of the HIV patients without
hepatitis co-infection had significant and 2% (5/327) severe
fibrosis (Fig. 1A).
Variables AssociatedWith Significant Liver Fibrosis
There were significant differences between the patients with
significant and severe fibrosis compared topatientswithLSvalues
7.1 kPa with regard to metabolic conditions like DM
(P< 0.001), duration of HIV infection (P¼ 0.002), exposure to
antiretroviral drug regimens containing azidothymidine (AZT),
stavudine (d4T), or didanosine (DDI) and interestingly also to the
duration thepatientwas treatment naive (P¼ 0.007;Table 1).Also
if LS values were not stratified, duration of HIV, treatment naive
time, and diabetes maintained a level of statistical significance
(Figure 1B–D). In contrast, age, sex, BMI, CD4þ T cell count
(nadir and actual values), and detectable HIV viremia were not
associated with abnormal LS.
FibroScan values, APRI score, and FIB4 score correlated
with each other highly significant (R¼ 0.218–0.754;
P< 0.001). Metabolic conditions (HbA1c, BMI), markers of
liver injury (AST, ALT, GGT, and bilirubin), renal function
(creatinine), and age correlated positively with LS, whereas
CRP and platelets showed an inverse correlation. Interestingly,
the total duration of HIV infection, the time the patient was
treatment naive, and the duration of cART showed all positive
correlations with LS values. FIB4 and APRI merely showed a
trend toward these variables (Table 2).
In theHIVmono-infected population significant differences
between the patients with fibrosis compared with patients with
Medicine  Volume 94, Number 50, December 2015normal LS values was observed with regard to diabetes
(P< 0.001) and the cumulative duration of HIV infection
(P¼ 0.01), obesity showed a trend toward statistical significance
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
by HIV viral load, was clearly associated with the risk of
TABLE 1. Baseline Subject Characteristics, Overall and by Significant Fibrosis as Determined by FS > 7.1 kPa
Characteristics All Subjects (n¼ 432) LS  7.1 kPa (n¼ 363) LS > 7.1 kPa (n¼ 50) P Value
Age, y 46 (38–53) 45 (38–52) 48 (43–55) 0.08
Male sex, n 336 (78) 275 (80) 38 (76) 0.70
Race, n
Caucasian 339 (79) 271 (79) 40 (80)
African 61 (14) 50 (15) 6 (12)
Asian 28 (7) 21 (6) 4 (8)
HIV transmission route, n
MSM 220 (51) 183 (53) 21 (42)
IDU 33 (8) 22 (6) 10 (20)
DM, n 23 (5) 13 (4) 8 (16) <0.001
BMI, kg/m2 25 (22–27) 25 (22–26) 26 (23–29) 0.09
>24, n 190 (44) 147 (45) 27 (56) 0.154
HCV, n 68 (16) 49 (14) 16 (32) 0.001
Duration of HIV, y 10 (5–15) 10 (5–15) 14 (8–18) 0.002
Nadir CD4þ, cells/mm3 239 (103–335) 232 (95–334) 208 (99–283) 0.21
Time naı¨ve, y 2 (0–3) 2 (0–3) 4 (0–6) 0.007
cART, n 410 (95) 326 (95) 49 (98) 0.29
Total cART duration, y 8 (3–13) 8 (3–12) 10 (3.5–16.0) 0.06
CDC-C, n 115 (27) 92 (27) 16 (32) 0.43
CD4þ count, cells/mm3 550 (367–698) 541 (374–686) 558 (311–704) 0.99
HIV viremia, >40c/mL 70 (16) 59 (16) 8 (16) 0.96
AST, U/L 25 (17–28) 24 (17–27) 36 (19–47) 0.006
Platelet count, G/L 221 (185–254) 224 (186–255) 191 (154–229) 0.001
FS, kPa 5.8 (4.1–6.1) 4.7 (4.0–5.6) 13.2 (7.6–13.5) <0.001
FIB4, IQR 0.99 (0.60–1.10) 0.88 (0.58–1.00) 1.85 (0.86–2.13) <0.001
APRI 0.3 (0.2–0.3) 0.2 (0.1–0.3) 0.6 (0.2–0.6) <0.001
Data are shown as median (IQR) or n (%)
apy
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Figure 1(E–H) shows that DM and BMI higher 25kg/m2 as well
as HIV infection longer 10 years and ART naive time greater 2
years are associated independently with higher LSM values in
HIV mono-infected subjects. In the co-infected patients, these
variables do not reach statistical significance and their effect on
fibrosis development might be exceeded by the much stronger
profibrogenic effect of viral hepatitis co-infection.
On univariate logistic regression analysis in HIV mono-
infected patients the duration of HIV infection, obesity, serum
triglyceride levels, diabetes, and the history of ART regimes
containing LPVr had a significant impact on abnormal LS
values. If taking into account the whole study population, serum
aminotransferases, platelet count, exposure to DDI, ART naive
duration, and chronic hepatitis C additionally showed signifi-
cant influence. On subsequent multivariate logistic regression
analysis cumulative HIV duration (odds ratio [OR]: 1.078; 95%
CI: 1.012–1.149), obesity (OR: 4.653; 95% CI: 1.424–15.199),
and diabetes mellitus (OR: 5.470; 95% CI: 1.812–16.513) were
selected as independent predictors accounting for abnormal
LS values in HIV mono-infected subjects (Table 3), whereas
HIV viral load was not associated with fibrosis development.
Per treatment naive year the risk of developing significant
fibrosis was found to rise by about 12% (OR: 1.12; 95% CI:
1.00–1.24). In a multivariate Cox regression analysis, taking
BMI ¼ body mass index, cART ¼ combination anti-retroviral ther
immunodeficiency virus, IDU¼ injecting drug user, IQR ¼ interquartilinto account the total duration of HIV infection, the cumulative
cART duration was demonstrated to have a protective effect on
liver fibrosis development (hazard ratio [HR]: 0.777; 95% CI:
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.0.712–0.847) and uncontrolled HIV viral replication, assessed
, DM ¼ diabetes mellitus, HCV ¼ hepatitis C virus, HIV ¼ human
nge, LS ¼ liver stiffness, MSM ¼ men who have sex with men.developing significant liver fibrosis (HR: 2.430; 95% CI:
1.095–5.396; Table 4).
DISCUSSION
This study demonstrated that presence of DM, obesity, as
well as HIV viral load were associated with presence of
significant fibrosis in HIV mono-infected patients. Also, HIV
infection is known to accelerate HBV and HCV-related liver
injury15–17 and is said to act independently as a profibrogenic
factor. However, previously published data largely rely on
studies using serum biomarkers17–22 for the assessment of liver
fibrosis and are likely to underestimate the magnitude of liver
disease. It is known that liver enzyme elevations are poor
markers of liver fibrosis or cirrhosis, especially in HIV-infected
patients.23,24 Moreover, studies using TE to assess fibrosis in
HIV mono-infected subjects were conducted with rather small
sample sizes.25–28 Our prospective study is the first in a large
cohort of HIV patients using TE and demonstrated a high rate of
moderate and severe fibrosis in the HIV-infected population
with a 10% prevalence of abnormal LS among HIV mono-
infected individuals and a markedly higher prevalence of
fibrosis in viral hepatitis co-infected patients.Our findings strongly indicate that HIV may also have a
direct effect on fibrogenesis, since HIV viral load was an
independent predictor in the time dependent Cox regression
www.md-journal.com | 3
FIGURE 1. (A) Distribution of fibrosis among subgroups. (B–D) Association between LS and HIV duration, time naive, and DM. (E–H)
Association between LS and BMI, DM, HIV duration, and time naive in HIV mono-infected patients compared with coinfected patients.
Data are presented as mean SEM. BMI ¼ body mass index, DM ¼ diabetes mellitus, HIV ¼ human immunodeficiency virus, LS ¼ liver
stiffness, SEM ¼ standard error of the mean.
Mohr et al Medicine  Volume 94, Number 50, December 2015
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TABLE 2. Correlations of Patient Characteristics and Clinical Parameters With Liver Fibrosis Assessed by FS, FIB4, and APRI
FibroScan FIB4 APRI
R P R P R P
Age 0.105

0.033 0.569

0.001 n.s.
HbA1c 0.170

0.002 n.s. n.s.
BMI 0.110

0.030 n.s. n.s.
AST 0.168

0.002 0.504

0.001 0.797

0.001
ALT 0.135

0.007 0.180

0.001 0.579

0.001
GGT 0.104

0.040 0.143

0.010 0.244

0.001
Bilirubin 0.115

0.040 0.239

0.001 0.228

0.001
Creatinine 0.151

0.005 0.282

0.001 0.160

0.004
Platelet count 0.137 0.006 0.618 0.001 0.637 0.001
CRP > 3 mg/dL 0.112 0.023 0.113 0.040 0.140 0.011
Duration of HIV 0.144

0.003 0.273

0.001 n.s.
Time naı¨ve 0.146

0.004 0.177

0.002 n.s.
cART duration 0.118

0.020 0.226

0.001 n.s.
BMI ¼ body mass index, cART ¼ combination anti-retroviral therapy, HIV ¼ human immunodeficiency virus, n.s. ¼ not significant.
Correlation is significant at the 0.05 level.
Correlation is significant at the 0.01 level.
TABLE 3. Evaluating Risk Factors for Increased Liver Stiffness by Logistic Regression: Uni- and Multivariate Analysis of the Cohort
and of HIV Mono-Infected Patients
Univariate Multivariate
P OR CI P OR CI
All subjects
Time naive 0.024 1.077 1.010–1.148
HIV infection duration 0.002 1.580 1.020–1.968 0.001 1.081 1.031–1.135
BMI 0.033 1.074 1.006–1.148
BMI > 30 kg/m2 0.003 1.588 0.864–2.920
DM 0.001 5.128 2.009–13.090 0.004 4.601 1.680–12.596
AST 0.002 1.036 1.013–1.060
ALT 0.001 1.023 1.010–1.035
GGT 0.021 1.005 1.001–1.009
Platelets 0.001 0.990 0.984–0.995
DDI history 0.011 1.342 0.149–1.781
LPVr history 0.005 1.414 0.225–1.763
Chronic HCV 0.001 1.339 0.175–1.660
FIB4 0.001 3.221 1.923–5.395 0.005 2.423 1.304–4.501
APRI 0.001 1.166 0.877–4.102
HIV mono-infected
HIV infection duration 0.030 1.600 1.006–1.811 0.021 1.078 1.012–1.149
BMI 0.043 1.084 1.002–1.173
BMI > 30 kg/m2 0.003 3.948 1.587–9.722 0.011 4.653 1.424–15.199
DM 0.001 6.196 2.114–18.164 0.003 5.470 1.812–16.513
Triglycerides 0.013 1.002 1.000–1.040
LPVr history 0.029 2.430 1.095–5.396
FIB4 0.002 3.453 1.585–7.520 0.008 3.312 1.370–8.004
APRI 0.031 2.554 1.319–5.691
BMI ¼ body mass index, CI ¼ confidence interval, DDI ¼ didanosine, DM ¼ diabetes mellitus, HCV ¼ hepatitis C virus, HIV ¼ human
immunodeficiency virus, LPVr ¼ lopinavir, OR ¼ odds ratio.
Medicine  Volume 94, Number 50, December 2015 Liver Fibrosis and cART in HIV
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TABLE 4. Cox Regression (Time Since HIV Diagnosis): Uni- and Multivariate Analysis in HIV Mono-Infected Patients
Univariate Multivariate
P HR CI P HR CI
cART duration 0.001 0.796 0.734–0.862 0.001 0.777 0.712–0.847
Body weight 0.058
BMI 0.065
ALT 0.034 1.018 1.001–1.035
HbA1c 0.026 1.107 1.012–1.211
HIV PCR 0.001 2.901 1.061–4.513 0.034 2.430 1.095–5.396
DM 0.028 1.360 1.145–1.894
AZT history 0.001 1.270 1.122–1.597
d4T history 0.002 1.257 1.110–1.602
FIB4 0.089
APRI 0.018 5.769 1.755–8.268
n a
d ra
Mohr et al Medicine  Volume 94, Number 50, December 2015analysis. Importantly, the time since HIV infection was inde-
pendently associated with higher fibrosis risk. The total duration
of HIV infection includes both, the ART naive period—con-
secutively the potential damaging effect of uncontrolled HIV
replication—and the time of antiretroviral treatment (with
possible hepatotoxic effects). Cumulative ART suggested a
protective effect on liver fibrosis development and HIV viral
replication was associated with a higher risk of liver fibrosis.
This goes along with in vitro data showing that HIV infects
human stellate cell lines, promotes proinflammatory cytokine
secretion, and favors fibrogenesis.5–7 More importantly, mar-
kers of liver fibrosis remodeling were significantly elevated in
HIV patients compared with healthy controls and correlated to
HIV viral loads and inversely to cART duration.29 Consistent
with our and other studies, the virological control offered by
cART is likely to protect against liver fibrosis.16,30–32 Our
findings suggest that successful cART and complete suppres-
sion of HIV replication beneficially influences and protects
liver fibrosis development. However, our study with the vast
majority of patients receiving antiretrovirals was not designed
to prove a beneficial impact of cART. With regard to exposure
to individual antiretrovirals, we found a direct relationship
between LS and exposure to regimens containing AZT, d4T,
or DDI, although this was not confirmed by multivariate
analysis. Importantly, cumulative cART exposure was not
associated with significant fibrosis. Our findings are consistent
with a recent report demonstrating that modern cART has a
negligible effect on liver fibrosis progression in HIV mono-
infected patients.33 While older antiretroviral drugs such as
AZT, d4T, and DDI might have increased the risk of liver
damage through hepatotoxicity, this effect might be counter-
balanced by a beneficial impact of newer and currently recom-
mended first-line regimens, which were applied in our
collective.
Besides that, known metabolic risk factors such as insulin
resistance (IR) are increasingly observed in patients infected
with HIV.34 It is unclear whether this is a direct effect of HIV
infection alone or a complication of antiretroviral drugs (eg.
protease inhibitors). Hyperglycemia and insulin stimulate
AZT¼ azidothymidine, BMI¼ body mass index, cART¼ combinatio
diabetes mellitus, HIV ¼ human immunodeficiency virus, HR ¼ hazarHSC,35 the key cells involved in the progression of fibrosis.11
Recent liver biopsy data confirm that the main cause of liver
damage of uncertain origin in HIV-infected patients was
6 | www.md-journal.comassociated with metabolic disorders; increase in BMI and
homeostasis model assessment—insulin resistance (HOMA-
IR) values higher than 2.6 were identified as the main risk
factors, while NASH was diagnosed as the main cause of liver
damage of uncertain origin.36 Interestingly, in our large pro-
spective study we could confirm that obesity and DM are risk
factors for presence of significant fibrosis in HIV patients with
and without HBV or HCV co-infection.
Our findings, together with other recently published data in
this field, might raise the question of whether the HIV-infected
population should be considered a high risk group for NAFLD
and should be screened as recommended by the AASLD in the
recent practice guidelines.37 An adequate monitoring of liver
disease and development of management algorithms are clearly
needed to optimize outcome and care of the aging HIV popu-
lation. The European AIDS Clinical Society guidelines recom-
mend regular determination of liver enzymes even in mono-
infected patients and when persistently elevated, after ruling out
other causes, annual noninvasive fibrosis stage assessment or
liver biopsy.38
The main limitations of this study are the cross-sectional
design, which limits the ability to evaluate change in variables
of interest over time, and the presence of a nonrandomized study
population. Alcohol consumption was self-reported by the
patient and this value may have been underestimated. More-
over, rare causes of liver disease (eg. hemochromatosis and
Wilson disease) were not specifically excluded. Finally, liver
biopsy remains the gold standard for the assessment of liver
fibrosis, but the acceptability and risk of biopsy make its
application difficult for a large study population. TE is non-
invasive and has been found to be accurate and reproducible in
determining the stage of liver fibrosis. New reliability criteria
for TE to increase the number of accurate measurements were
recently published, but the applied criteria were classified as
reliable and accurate for the diagnostic performance of signifi-
cant fibrosis.39
In conclusion, the correlation between HIV-related viro-
logical status and LS suggests that HIV itself together with the
metabolic profile might promote liver fibrosis. These findings
nti-retroviral therapy, CI¼ confidence interval, d4T¼ stavudine, DM¼
tio, PCR ¼ polymerized chain reaction.underscore that in aging with HIV the interplay and additive
effects of different factors might be crucial for the development
of liver disease. Modern cART regimes beneficially influence
Copyright # 2015 Wolters Kluwer Health, Inc. All rights reserved.
33. Moodie EEM, Pant Pai N, Klein MB. Is antiretroviral therapyliver fibrosis. However, further long-term prospective studies
are needed. A regular assessment of liver fibrosis in HIV mono-
infected patients seems to be advisable.
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